Unilever Australia Ltd v Revlon Australia Pty Ltd (No 3)

Link copied
Case Copied 11 min read

FEDERAL COURT OF AUSTRALIA

Unilever Australia Ltd v Revlon Australia Pty Ltd (No 3) [2014] FCA 1005

Citation: Unilever Australia Ltd v Revlon Australia Pty Ltd (No 3) [2014] FCA 1005
Parties: UNILEVER AUSTRALIA LIMITED (ACN 004 050 828) v REVLON AUSTRALIA PTY LTD (ACN 095 360 731)
File number: NSD 508 of 2014
Judge: GLEESON J
Date of judgment: 16 September 2014
Catchwords: PRACTICE AND PROCEDURE – confidentiality orders – whether confidential exhibits to respondent’s affidavit may be disclosed to applicant’s in house counsel – whether exhibits may be disclosed to other persons for purposes of the proceedings – where parties are trade rivals – where documents would be subject to usual implied undertaking  
Legislation: Federal Court of Australia Act 1976 (Cth) s 50
Cases cited: Autodata Ltd v Boyce’s Automotive Data Pty Ltd [2007] FCA 1517
ICAP Australia Pty Ltd v Moebes [2010] NSWSC 738
Cyclopet Pty Ltd v Australian Nuclear Science and Technology Org [2012] FCA 1326
Forty Two International Pty Ltd v Barnes (No 4) [2012] FCA 1059
Date of hearing: 11 September 2014
Place: Sydney
Division: GENERAL DIVISION
Category: Catchwords
Number of paragraphs: 21
Counsel for the Applicant: Mr Richard Cobden SC
Solicitor for the Applicant: Baker & McKenzie
Counsel for the Respondent: Mr Michael Hall with Ms Edwina Whitby
Solicitor for the Respondent: King + Wood Mallesons

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 508 of 2014

BETWEEN:

UNILEVER AUSTRALIA LIMITED (ACN 004 050 828)
Applicant

AND:

REVLON AUSTRALIA PTY LTD (ACN 095 360 731)
Respondent

JUDGE:

GLEESON J

DATE OF ORDER:

16 SEPTEMBER 2014

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.Despite any confidentiality undertaking concerning documents including exhibits MDT-27, MDT-28 (as redacted), MDT-30 and MDT-32 referred to in the third affidavit of Dr Michael David Traudt sworn 3 September 2014, each of those documents may be disclosed to any person for the purpose of these proceedings.

Note:Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.


IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

GENERAL DIVISION

NSD 508 of 2014

BETWEEN:

UNILEVER AUSTRALIA LIMITED (ACN 004 050 828)
Applicant

AND:

REVLON AUSTRALIA PTY LTD (ACN 095 360 731)
Respondent

JUDGE:

GLEESON J

DATE:

16 SEPTEMBER 2014

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. The applicant/cross-respondent (“Unilever”) applies for an order that, in substance, authorises the use of four documents received from the respondent/cross-claimant (“Revlon”) pursuant to confidentiality undertakings. The terms of the undertakings are:

    1.Subject to any Order of or authorisation by the Court, or without the written consent of the Respondent through its solicitors to the contrary, and further subject to paragraph 2 below:

    (a)I will keep the documents and information confidential at all times and will not disclose them (either in whole or in part) either directly or indirectly to any person including the parties to these proceedings, their in-house counsel, any company within the Unilever group of companies or the respective employees and agents of…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Unilever Australia Ltd v Revlon Australia Pty Ltd (No 3) and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2014] FCA 1005
Decision Date

CaseChat Overview and Summary

Unilever Australia Ltd v Revlon Australia Pty Ltd (No 3) involved a dispute between the two companies over the confidentiality of certain documents related to product testing and efficacy. The primary issue before the court was whether the documents, which were confidential exhibits to Revlon's affidavit, could be disclosed to Unilever's in-house counsel and other persons involved in the proceedings. The documents in question were four reports related to clinical evaluations of deodorant products, and Revlon argued that they contained confidential information about their testing processes and methods. In contrast, Unilever argued that the documents were not particularly sensitive and their disclosure would not disadvantage Revlon.

The court considered the evidence provided by both parties and examined the documents in question. The court noted that the documents contained information about Revlon's testing processes and methods, but also contained results of the clinical evaluations. The court found that the degree to which the differences between the information in the disputed documents and the previously disclosed document were commercially sensitive was not obvious. The court concluded that the information claimed to be confidential was not particularly sensitive, and that its disclosure would not confer any material advantage upon Unilever or cause Revlon any material disadvantage.

The court held that the four documents should be disclosed to any person for the purpose of these proceedings, subject to the usual implied undertaking. The court found that the opinions expressed by Dr Traudt upon the basis of the four documents were central to one aspect of the dispute between the parties, namely the reasonableness of Revlon’s representations as to the efficacy of the Mitchum Clinical Strength “Oxygen Roll-On”. The court did not accept Revlon's contention that it would be reasonable for Unilever to be restricted to addressing this evidence through independent experts without the benefit of instructions concerning the document, or the opportunity to obtain evidence in reply from one or more Unilever employees.

Orders

Orders of the court

1. Despite any confidentiality undertaking concerning documents including exhibits MDT-27, MDT-28 (as redacted), MDT-30 and MDT-32 referred to in the third affidavit of Dr Michael David Traudt sworn 3 September 2014, each of those documents may be disclosed to any person for the purpose of these proceedings.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Dr Traudt concludes that the results of the 2012 clinical evaluation, when compared to the 2011 clinical evaluation, demonstrated to him that the addition of hydrogen peroxide to the formulation was clinically meaningful or measureable. He considered in 2012, and still considers, that the results show that hydrogen peroxide has an odour benefit. Dr Traudt says that his opinion is strengthened by the statistical comparative analysis in MDT-32. Revlon’s evidence of confidentiality Dr Traudt’s 3 September 2014 affidavit contains the following evidence (additional to the descriptions of the documents) relied upon in support of the confidentiality claim:a.the testing processes and methods used by Revlon are kept confidential from trade rivals;b.whilst the methodology itself is not necessarily a confidential methodology, the knowledge of which methodology is used for which products and when is confidential information about the trade and testing processes undertaken by Revlon;c.this information could be used by a competitor to the disadvantage of Revlon. In oral submissions, Mr Hall, counsel for the respondent, argued that the nature of the reports was itself relevant to a determination of their confidentiality because they are revealed to be commercial research conducted by Revlon for internal purposes, independently of the litigation, to assess the efficacy of products that it is considering offering to the market or offering to the market. Mr Hall said that Dr Traudt’s evidence should be read as a statement about the practice and policy of Revlon to preserve secrecy as to which methodology is used for which products and when.Matters relied on by Unilever Unilever relies on the following propositions to contend that the documents are not confidential:a.The methodology which is claimed to be confidential is disclosed in overview terms in Dr Traudt’s affidavit. In oral submissions, Mr Cobden SC, senior counsel for the applicant, said that paragraph 6 of Dr Traudt’s affidavit revealed that the 2011 clinical evaluation was a test of the relevant product (the Original Roll-On) against untreated armpits. Mr Hall did not dispute this interpretation of Dr Traudt’s evidence.b.The relevant methodology is disclosed in the redacted version of exhibit MDT-10, which is a document that the Court has previously permitted (by order made on 19 June 2014) to be disclosed to Jonathon Friedrich, Unilever’s in house counsel, and any person to be called as a witness by Unilever in the proceedings. c.MDT-10 is a report of a clinical evaluation of the deodorant efficacy of the Original Roll-On with hydrogen peroxide conducted in 2013. It appears from the Court’s 19 June 2014 order that redactions were made only to prevent disclosure of references to a second product the subject of the clinical evaluation, being a product not the subject of the proceedings. d.I was informed from the Bar table that Ms Carvell has seen the redacted version of MDT-10.e.There is no evidence as to how knowledge of which methodology may be used for which product and when could be used by a commercial rival. f.The proposition (e) gains force because the tests were conducted 2 and 3 years ago.

Decision

Reasons for decision

I am not satisfied that the information claimed to be confidential (which is only a subset of the information in the reports) is particularly sensitive, or that its disclosure upon the terms of the usual implied undertaking could confer any material advantage upon Unilever, or cause Revlon any material disadvantage. On the other hand, I accept Unilever’s submission that the opinions expressed by Dr Traudt upon the basis of the four documents is central to one aspect of the dispute between the parties, namely the reasonableness of Revlon’s representations as to the efficacy of the Mitchum Clinical Strength “Oxygen Roll-On”. I do not accept Revlon’s contention that it would be reasonable for Unilever to be restricted to addressing this evidence through independent experts without the benefit of instructions concerning the document, or the opportunity to obtain evidence in reply from one or more Unilever employees.Conclusion Disclosure and use of MDT-27, MDT-28 (as redacted), MDT-30 and MDT-32 should be permitted subject only to the usual implied undertaking that they be used only for the purposes of the proceedings.

Ratio Decidendi

Legal Principle Established

As to the need to access the documents, Unilever made the following submissions:a.The conclusions drawn by Dr Traudt on the basis of the material in the four documents are “absolutely central” to the reasonable belief case in respect of which his affidavit is put forward;b.Unilever wishes to show the documents to Mr Friedrich, Ms Carvell, and to one or more other potential witnesses who are employees of Unilever, and any others who might assist Unilever in the review of the documents;c.As to Ms Carvell, she has given an affidavit in the proceedings dealing with comparative product testing of the same nature as the tests which are the subject of exhibits MDT-28 and 30 (without any claims for confidentiality by Unilever other than as to product formulation);d.Unilever needs to take the steps in (b) above in order to prepare its evidence in reply. Consideration I have examined the four disputed documents, as well as MDT-10. That examination revealed the following:a.the information in the documents is not solely concerned with Revlon’s testing processes and methods. For example, MDT-27, MDT-28 and MDT-30 also contain the results of the various clinical evaluations. Those results are disclosed at paragraph 24 of Dr Traudt’s affidavit;b.to the extent that the format of the report might be said to disclose confidential information about Revlon’s testing processes and methods, that format has been disclosed by exhibit MDT-10;c.there are some differences between the information about Revlon’s testing processes ad methods in the four disputed documents and MDT-10. The degree to which those differences are commercially sensitive is not obvious. The evidence is not that the methodology disclosed in the documents is confidential per se, but rather that the use of the particular methodology for the relevant products at the relevant time is confidential information which is entitled to protection. In the absence of more detailed evidence, and having reviewed the documents, I am unable to determine how the documents could be used by a competitor to the disadvantage of Revlon, and whether any disadvantage might be significant. When considering a claim of confidentiality, it is relevant to consider whether the documents the subject of the claim possess “the necessary quality of confidence” about them, and whether the preservation of the documents’ confidentiality is of substantial concern to the person making the claim: cf Autodata Ltd v Boyce’s Automotive Data Pty Ltd [2007] FCA 1517 at [10]. I can readily accept that the documents contain information about Revlon’s testing processes and methods that are, in fact, kept confidential and may satisfy the tests for confidentiality. It is next necessary to consider whether the documents warrant the protection currently afforded to them by the confidentiality undertakings: cf ICAP Australia Pty Ltd v Moebes [2010] NSWSC 738 at [8] (“ICAP”); Cyclopet Pty Ltd v Australian Nuclear Science and Technology Org [2012] FCA 1326 at [6] (“Cyclopet”)